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ABSTRACT. Given a certain technology or procedure for diagnostic testing, different 
cutoff points produce different sensitivity and specificity rates. The cutoff point that 
generates highest sensitivity and specificity establishes the Criterion Standard Test 
(otherwise known as the Gold Standard Test). If, subject to good reason, a new 
testing technology or procedure emerges, the optimum cutoff point associated with it 
may generate higher sensitivity and specificity and thus a new improved Criterion 
Standard Test. Various cutoff selection methodologies have been proposed, all based 
on Euclidean geometry, involving the so-called Receiver Operating Characteristic 
(ROC) curve. Our purpose in this paper is to recommend a new selection method- 
ology based on the P-Value associated with the well-known Pearson’s chi-squared 
test (χ2) – the conventional test utilized when testing for dependence between state 
of nature (disease present or not present) and evidence (test positive or negative  
measures). Using a hypothetical numerical example, we demonstrate that the cutoff 
point associated with the lowest P-Value of the Pearson’s chi-squared test is the one 
that maximizes sensitivity and specificity, or overall accuracy, thus establishing the 
Criterion Standard Test. Although the best geometric method (sums of squares) and 
the proposed method are equally effective in selecting the optimum cutoff point, only 
the proposed new procedure selects based on statistical significance. Additionally, 
we propose a simple theoretical benefits / costs linear setting to discuss the impor- 
tance of net benefits associated with testing accuracy and reference harmful as well 
as beneficial testing cases found in various literature sources.  
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Epidemiological studies, genetic theory, clinical studies, and testing for effi- 
cacy of new medicine and medical devices or procedures, enable researchers 
and regulatory authorities to estimate probabilities in their efforts to deal  
with the diagnosis and cure of a disease or, alternatively stated, to minimize 
false-positives (F+) and false-negatives (F-) that impose costs on society 
including poor medical outcomes, direct costs associated with less efficient 
care, inappropriate use of therapies and diagnostic tests, lost patient  
productivity (e.g., increased absenteeism), and administrative burden.  
     For example, an epidemiological study establishes state of nature proba- 
bilities (or prior probabilities such as the prevalence of a disease in a human 
population) against which a researcher may test the efficacy of a new medi- 
cine or the sensitivity of new diagnostic test or medical device / procedure. 
Similarly, after genetic theory (e.g., applied to autosomal recessive diseases) 
establishes prior probabilities, whether an individual carries a disease may be 
tested subject to optimal cutoff points (cutoff points that maximize test 
accuracy). Also, clinical studies enable researchers to test their hypotheses 
(e.g., how likely it is that, given symptoms, a patient carries a disease) based 
on prior probabilities derived from literature and their clinical experience. 
Likewise, the U.S. Food and Drug Administration (FDA) requires that the 
safety of food and cosmetics, and the safety and efficacy of drugs and medical 
devices are tested and validated or demonstrated.1 
     Recent epidemiological studies have dealt with physicality of older women 
in Scotland (Yang et al., 2017), children with disorders (Katusic et al., 
2017), ageing (Lu et al., 2016), and immunology (Black at al., 2016) as well 
as mind-body therapy (Bower et al., 2016). 
     Additionally, clinical research efforts, facilitated by the FDA, have been 
producing safer, faster and more effective outcomes; most notably, see Zarin 
et al. (2016) on trial reporting, Schwartz et al. (2016) on new drug approval, 
Bourgeois et al. (2016) on intervention trials, Russek-Cohen et al. (2011) on 
diagnostic devices, and Ziegler et al. (2005) on radiology technologies. 
Undoubtedly, the research effort has been aided by the digital revolution 
which has greatly contributed to improved diagnostic accuracy and screen- 
ing; see, among many others, Willis et al. (2011), Albert (2009), Zhou et al. 
(2011), Zou et al. (2011), and Ballard-Barbash et al. (1997). 
     Moreover, genomic testing studies have been pushing the evolutionary 
frontier across the board; specifically, studies by Nair et al. (2016) on  
endometrial cancer, Stranneheim et al. (2016) on monogenic disorders, Van 
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Driest et al. (2016) on arrhythmia, Gonzaga-Jauregui et al. (2012) on general 
lessons associated with human genome sequencing in health and disease,  
Gepts (2014) on genetic and genomic approaches to plant domestication 
studies, and Manrai et al. (2016) on genetic misdiagnoses.  
     Many researches involved in such studies rely on the Bayesian Theorem 
to derive posterior probabilities based on prior probabilities. According to 
Copi et al. (2007), Thomas Bayes was “the first to use probability induc- 
tively and who established a mathematical basis for probability inference: a 
means of calculating, from the frequency with which an event has occurred 
in prior trials, the probability that it will occur in future trials.”2 
     Bayesian learning starts with some initial information about an event X 
which enables the researcher to estimate the probability of event X occurring; 
in turn, in the next period, if additional or better information becomes  
available a new probability is estimated (the posterior probability) given the 
probability estimated in the previous period (the prior probability) and so 
forth for any n periods. In every new period a new posterior probability is 
estimated which becomes the prior probability in the next period. Hence, 
since the posterior probability is based on more and / or better information, it 
contributes to more and / or better knowledge; it takes us closer to the truth 
but inductively so: the process generates a probable credible result but not a 
certain one. Flow Chart 1 sketches this process.3 
     When evaluating a diagnostic test or procedure, different cutoff points 
produce different sensitivity and specificity rates. The cutoff point that  
generates the highest sensitivity and specificity establishes the Criterion 
Standard Test (otherwise known as Gold Standard Test). Of course, if a new 
diagnostic test or procedure emerges, the optimum cutoff point associated 
with it may generate higher sensitivity and specificity and thus a new im- 
proved Criterion Standard Test. It is also likely that a new testing technology 
or procedure generates reduced accuracy in which case we revert to the  
previous Criterion Standard Test. 
     Various cutoff selection methodologies have been proposed, all based on 
Euclidean geometry, involving the so-called Receiver Operating Characteristic 
(ROC) curve. Our purpose in this paper is to recommend a new selection 
methodology based on the P-Value associated with the well-known Pearson’s 
chi-squared test (χ2) when testing for dependence between state of nature 
(disease present or not present) and evidence (test positive or negative  
measures). Using a numerical example, we shall attempt to demonstrate that 
the cutoff point associated with the lowest P-Value of the Pearson’s chi-
squared test is the one that maximizes sensitivity and specificity, or overall 
accuracy, thus establishing the Criterion Standard Test. 
     We proceed as follows: in Section 2, we review the existing cutoff 
methodologies. In Section 3, we offer a hypothetical numerical example that 
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involves diagnosing cancer with positron emission tomography (PET) and 
the measure it produces called standardized uptake value (SUV) – an indicator 
of how likely the part of the body contains cancerous cells. In Section 4, we 
take the opportunity to discuss some Criterion Standard Test applications 
found in the literature and we stress the importance of false-positives and 
false-negatives as costs to society in the discovery process for new 
diagnostic test / procedure and medicine. Finally, in Section 5 we summarize 
and conclude. Appendix 1 describes the Bayesian Theorem (statement, proof 
and examples) which may be skipped by readers familiar with it. All  
hypothetical data used in Section 3 is in Appendix 2. 
 
Flow Chart 1 Bayesian Learning  
(P = Probability, K = Knowledge, t = time ranging from 1 to n) 
 
 
2. Cutoff Methodologies 
 
Existing cutoff methodologies are eloquently described by Froud and Abel 
(2014) in conjunction with the well-known Receiver Operator Characteristic 
(ROC) curve which maps “Sensitivity” (vertical axis) vs. “1-Specificity” 
(horizontal axis).4 They propose a methodology for the identification of 
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optimal cutoff points which outperforms the Farrar method and the EMGO 
method. In their words, “to identify Minimally Important Change (MIC) 
thresholds on scales that measure a change in health status … we choose the 
point in ROC space that minimizes [QFA] … the sums of squares of 1-sens 
and 1-spec” where QFA = min {(1-Sensitivity)2 + (1-Specificity)2}. 
     Assuming that three possible points on the ROC are A, B, and C, Figure 1 
describes the Euclidean geometry associated with the Froud-Abel selection 
result (point A) relative to Farrar (point B) and EMGO (point C). Since the 
objective is to select the point on the ROC closest to (0,1), or closest to the 
northwest point, clearly the Froud-Abel method outperfoms the other two. 
(The circle, or the equidistant frontier , is centered around the top-left 
corner; the equidistant frontier passing through A is closer to the top-left 
corner relative to the frontiers that pass through B and C). For a different 
approcah on how to search for optimal cutoff points see Terluin et al. (2015).  
 
Figure 1 The Froud-Abel Method  
[Euclidean geometry associated with the Froud-Abel selection result  
(point A) relative to Farrar (point B) and EMGO (point C)] 
 
Alternatively, as we propose in this paper and show below by way of  
hypothetical example, the cutoff point that establishes the Criterion Standard 
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Test is the one that corresponds to the lowest P-Value of the Pearson’s chi-
squared test (χ2). More specifically, when testing for the existence of depen- 
dence between the state of nature variable (disease present or not present) 
and the hypothesis or evidence variable (test positive or negative measures) 
using the χ2 test, in most applications, we end up with many cutoff points 
that enable us to reject the zero hypothesis H0 (the state of nature variable 
and the hypothesis variable are independent) in favor of the al ternative 
hypothesis H1 (the state of nature variable and the hypothesis variable are not 
independent); hence, which one of the many cutoff points that generate  
statistically significant results should be selected? We propose that the cutoff 
point that generates the lowest P-Value ought to be considered as the Crite- 
rion Standard Test. In conventional research, the gold standard is reported 
void of statistical significance; as such, it is less useful in decision making 
involving screening and diagnostic testing or in the process of medicine 
discovery. The proposed methodology adds statistical significance to the 
process of establishing maximum accuracy (or a gold standard) thus making 
decisions more credible. Using a fictitious numerical example, we show 
below that the lowest P-Value of the χ2 test corresponds to the cutoff point 
identified by the Froud-Abel Method as well.  
 
3. Hypothetical Numerical Example 
 
Positron emission tomography (PET), among other applications, may be used 
to diagnose cancer. PET generates a standardized uptake value (SUV) which 
serves as an indicator of the likelihood of cancer. SUV is a positive number 
ranging from 0 upwards; the higher the SUV value the more likely it is that 
cancer is present. A value greater than 10 implies a high likelihood for  
aggressive disease. After SUV is measured the patients undergo a biopsy 
wherein a small piece of tissue from the suspected area is removed and 
examined histologically and/or genetically sequenced to inform a cancer  
diagnosis. Pathological verification along these lines gives rise to the so-
called gold standard.   
     In the table that appears in Appendix 2 we report hypothetical data for 
100 individuals: first column – identification of subjects (ID), second column 
– SUV scores, and third column – biopsy results for Cancer where 1 = present 
and 2 = not present. Figure 2 reports the sample probability distributions of 
SUV tested positive (top) and tested negative (bottom); it shows that higher 
SUV scores are more likely to be associated with cancer than otherwise and 
it clearly demonstrates the impact of cutoff point regarding false-positives 
and false-negatives: when the cutoff point is increased from the left double-
headed arrow to the right double-headed arrow, false-positives decrease and 
false-negatives increase.5 For “treatable” cancer, a test that generates a high 
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number of false-negatives is not a good test and undoubtedly more prob- 
lematic than a test that generates a high number of false-positives. False-
positives would cause psychological discomfort and unnecessary treatment, 
sometimes even surgery or chemotherapy, but, false-negatives, may delay 
treatment and could lead to loss of life. On the other hand, if the disease is 
incurable a false-negative diagnosis may not be that bad. Hence, at least for 
treatable diseases, quickly identifying optimum cutoff points is of paramount 
importance. 
 
Figure 2 The need for optimum cutoff point 
(P = Probability, SUV = Standardized Uptake Value)  
      
To discover the optimum cutoff point (or, the cutoff point that would give 
rise to the Criterion Standard Test), we proceeded as follows: based on the 
distribution of SUV scores, we constructed all possible 2-variable contingency 
tables per SUV value – as the one below for SUV = 10 – and, using the χ2 
test, we tested whether or not the state of nature variable and the test results 
variable are independent. (Details regarding such contingency tables may be 




For 20 SUV discrete scores, Table 1 reports the following: SUV score and 
corresponding Sensitivity, Specificity, the Froud-Abel sums of squares (QFA) 
result, and the P-Value of each test based on the χ2. Figure 3 reports the 
corresponding ROC line. The results show that the optimum cutoff point is 
SUV = 8. This point is picked by the Froud-Abel method (lowest QFA) as 
well as by our proposed new method which relies on the χ2 test and the 
lowest P-Value associated with it. Although the two methodologies are 
equally effective in selecting the optimum cutoff point, only the proposed 
new procedure selects based on statistical significance: it ranks cutoff points 
according to the P-Value of the χ2 test and selects the one that corresponds to 










       Table 1 Criterion Standard Test: Similarity between Froud-Abel and new method 
SUV Sensitivity Specificity QFA P-Value (χ2 test) 
1 1 0.13636 0.74587405 0.0225905662698 
2 1 0.25760 0.55115776 0.0011245653222 
3 1 0.57580 0.17994564 0.0000000200954 
4 1 0.69700 0.09180900 0.0000000000389 
5 0.9411 0.75760 0.06222697 0.0000000000346 
6 0.9118 0.80300 0.04658824 0.0000000000090 
7 0.8529 0.86360 0.04024337 0.0000000000027 
8 0.8529 0.87880 0.03632785 0.0000000000007 
9 0.7941 0.87880 0.05708425 0.0000000000234 
10 0.7647 0.87880 0.07005553 0.0000000001235 
11 0.7353 0.89390 0.08132330 0.0000000001778 
12 0.6765 0.89390 0.11590946 0.0000000037146 
13 0.6176 0.96970 0.14714785 0.0000000042114 
14 0.4706 0.96970 0.28118245 0.0000000523462 
15 0.3529 1.00000 0.41873841 0.0000002948080 
16 0.2353 1.00000 0.58476609 0.0000361425549 
17 0.1765 1.00000 0.67815225 0.0003544775043 
18 0.1176 1.00000 0.77862976 0.0053934345806 
19 0.0588 1.00000 0.88585744 0.0515240209908 
20 0.0294 1.00000 0.94206436 0.1248516808144 
 
       Figure 3 ROC 
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4. Net Benefits of “Accuracy” 
 
The pursuit of accuracy (A) from successive diagnostic tests, where A = 
[(TP + TN) | (TP + TN + FP + FN)], 0 ≤ A ≤ 1, offers improved outcomes, 
in general, health benefits (HB) and, simultaneously, imposes costs to all  
parties involved such as testing costs and harms (TC). HB and TC depend on 
many variables: testing procedures (with direct risks – for example, anesthesia; 
and indirect risks – for example, stress of testing), laboratory procedures 
regarding handling of samples and quality of test administration, availability 
of follow-up tests, potential interference with subsequent tests, and other 
such variables.  
     Therefore, we believe, it would be logical to express, rather simplistically 
but without loss of generality, HB and TC as functions of just A such as HB 
= A – 1/2A2 and TC = αA2, where α = constant. The derivatives of these 
functions with respect to A are MHB = 1 – A and MTC = 2αA, where MHB 
stands for Marginal Health Benefits and MTC for Marginal Testing and 
Harm Costs.  
Figure 4 displays, with $ on the vertical axis and A on the horizontal, the 
MHB curve together with three MTC curves at various values of α where α 
may be viewed as an indicator of cost sensitivity. Benefits are maximized at 
A = 1, the point of maximum accuracy.  
 
   Figure 4 Marginal Health Benefits and Marginal Testing and Harm Costs 
 
At the point of maximum A (A=1), the entire area under the MHB curve 
corresponds to total benefits (TB) and the entire area under the MTC curve, 
given α, corresponds to total testing and harm costs (TC). The net benefit  
(NB) is greater than zero when α < 0.5. 
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In the pursuit of accuracy improvement, undoubtedly, innovation in test- 
ing, new medical devices and new medicine are difficult, complex and delicate 
processes that require proper incentives, precautions, and effective regulatory 
directives with the objective to optimize net health benefits. Although  
estimation of net benefits ought to be undertaken for each individual test as 
well as for the whole healthcare industry, it is not our objective to do so in 
this paper; for useful papers along these lines, especially on cost-utility 
methodology, see Vanhook (2007) and Wright et al. (2012). However, we 
believe it would be worthwhile to reference some published reports regarding 
diagnostic testing accuracy and the net benefit implications associated with it.  
     In a recent report the FDA [Food and Drug Administration (2015)]  
informs the public about harmful costs due to false-positives and false-
negatives as well as due to treatments based on refuted concepts and in- 
accurate or untrustworthy tests; as reported in the executive summary (p. 2), 
 
[l]aboratory developed tests (LDTs) serve an increasingly important 
role in health care today. They also have become significantly more 
complex and higher risk, with several notable examples of in- 
accurate tests placing patients at otherwise avoidable risk … [de- 
spite the fact that the examined laboratories] follow the minimum 
requirements of Clinical Laboratory Improvement Amendments 
(CLIA) …  
     We examined events involving 20 LDTs that illustrate, in the 
absence of compliance with FDA requirements, that these products 
may have caused or have caused actual harm to patients. In some 
cases, due to false-positive tests, patients were told they have con- 
ditions they do not really have, causing unnecessary distress and 
resulting in unneeded treatment. In other cases, the LDTs were 
prone to false-negative results, in which patients’ life-threatening 
diseases went undetected. As a result, patients failed to receive 
effective treatments.  
     Other LDTs provided information with no proven relevance to 
the disease or condition for which they are intended for use, while 
still others are linked to treatments based on disproven scientific 
concepts. In addition to patient harm, inaccurate or unreliable tests 
can be costly to society. We estimated these costs, if sufficient 
data were available. 
 
Summaries of some FDA reports on LDTs are displayed in Table 2 (clinical 
consequence highlighted). The summaries correspond to a test that produced 
many false-positives (ovarian cancer – top), a test that produced many false-
negatives (breast cancer – bottom), and a test that produced both many false-




Table 2 Three inaccurate tests as reported by the FDAa  
           
OvaSure™ Ovarian Cancer Screening Test  
Category LDT Characteristics 
LDT Name   OvaSure Screening Test  
Description 
Blood test on four biomarkers based on initial research in  
the published literature reporting an association with ovarian 
cancer 
Purpose  Screen for and detect ovarian cancer   
Target Population  Women at risk for ovarian cancer  
Alternatives  Other biomarkers or physical symptoms  
LDT Problem 1  No validation that test predicts or detects ovarian cancer  
LDT Problem 2  
Inflated PPV claims by the manufacturer, so many patients 
with a positive test won’t have the disease  
Clinical Consequence  
Women with false-positive tests may undergo   
unnecessary surgery to remove healthy ovaries  
Potential Impact of FDA  Assurance the test meets minimum performance standards  
Oversight  Evaluation of manufacturer claims  
Cost Impact of Inaccuracy  $12,578 per ovary removal after false-positive  
aSource: Food and Drug Administration (2016) – Office of Public Health Strategy and 
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of 
Laboratory Developed Tests: 20 Case Studies,” November 16, 2015. 
 
Oncotype DX HER2 Breast Cancer RT-PCR Test  
Category LDT Characteristics 
LDT Name  Oncotype DX HER2 RT-PCR  
Description  Rapid PCR test for tumor HER2 receptors  
Purpose  Use HER2 receptor level to guide treatment  
Target Population  Newly diagnosed Stage I and II breast cancer patients  
Alternatives  FDA-approved HER2 receptor tests  
LDT Problem 1  
Test has poor sensitivity – many tests reported as normal 
HER2 levels will actually have high HER2 levels  
Clinical Consequence  
Patients with false-negative tests won’t receive  
appropriate treatment, and cancer may progress  
Potential Impact of FDA  Assurance the test meets minimum performance standards  
Cost Impact of Inaccuracy  $775,278 estimated cost per false-negative case  
aSource: Food and Drug Administration (2016) – Office of Public Health Strategy and 
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of 








Noninvasive Prenatal Testing (A.K.A. cell-free DNA testing)  
Category LDT Characteristics 
LDT Name    
Noninvasive prenatal cell-free DNA testing (NIPT, or 
cfDNA)  
Description  
Blood test to identify traces of fetal chromosomes in  
maternal blood  
Purpose  To detect a range of fetal chromosomal abnormalities  
Target Population  
Pregnant women concerned about a fetal chromosomal 
abnormality  
   Alternatives 
Invasive testing, including amniocentesis and  
chorionic villi sampling; “quad testing” of multiple  
substances combined with ultrasound imaging 
LDT Problem 1  
Lack of clinical validation that tests detect and predict  
fetal abnormalities at an appropriate rate  
LDT Problem 2  
Many false-positive results when used in the general 
population  
Clinical Consequence  
Women with false-positive results may abort a  
normal pregnancy; women with false-negative  
results may deliver a child with an unanticipated  
genetic syndrome  
Potential Impact of FDA Oversight  
Assurance the test meets minimum performance  
standards; evaluation of manufacturer claims  
Cost Impact of Inaccuracy  Not estimated  
aSource: Food and Drug Administration (2016) – Office of Public Health Strategy and 
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of 
Laboratory Developed Tests: 20 Case Studies,” November 16, 2015. 
 
But, tests are not all harmful. Lewis (2016) describes the immense benefit 
and the very low cost of an ingenious new diagnostic test for the Zika virus 
based on CRISPR/Cas9 gene-editing (a new approach in testing which relies 
on genome tinkering with demonstrated potential to edit DNA in cell lines 
and embryos, a methodology that has spurred international discussion about 
ethical, legal and social issues). In Lewis’ words,  
 
[s]cientists have developed a cheap, rapid, paper-based diagnostic 
test for Zika virus. … [which] takes only two to three hours …  
Using CRISPR/Cas9 gene-editing, the test is capable of dis- 
tinguishing between different strains of Zika .... The Cas9 enzyme 
selectively targets and cleaves DNA synthesized from viral RNA 
only if a specific sequence is present, rendering it undetectable by 
the RNA sensor. If the sequence is not present, the DNA is not 
cleaved and the virus will be detected. Each test costs less than $1, 
and can be stored at room temperature for up to a year. 
 
The above examples of unsuccessful and successful diagnostic tests imply 
(a) that the value of a diagnostic test ultimately lies in its effect on patient 
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outcomes, (b) that a new test should only be introduced into clinical practice 
if it is more likely that it would contribute to improving health outcomes, 
and (c) that decision-making regarding a new test ought to involve selecting, 
from among many competing tests, the one that generates the highest level 
of accuracy.  
 
5. Summary and Conclusion 
 
In the sections above, we reexamined how the Criterion Standard Test  
(otherwise known as the Gold Standard Test) is determined in diagnostic 
testing, and we proposed a new selection methodology based on the P-Value 
associated with the well-known Pearson’s chi-squared test (χ2), the test used 
when testing for dependence between state of nature (disease present or not 
present) and evidence (test positive or negative measures). With the assistance 
of a hypothetical numerical example, we demonstrated that the cutoff point 
associated with the lowest P-Value of the Pearson’s chi-squared test is the 
one that maximizes overall accuracy, thus establishing the Criterion Standard 
Test. Although our methodology and the sums of squares approach are  
equally effective in selecting the optimum cutoff point, only the proposed 
new procedure selects based on statistical significance. Additionally, using a 
simple benefits / costs theoretical linear setting, we discussed the importance 
of net benefits of testing for accuracy and referenced harmful as well as 
beneficial diagnostic tests found in various literature sources.  
     In general, the proposed statistician test may be readily employed in any 
biomedical testing procedure described by the National Center for Biotech- 
nology Information (2017) and, more specifically, in conjunction with 
research involving biomarkers, such as estrogen (ER) and progesterone (PR) 
receptors, in breast cancer (see Varga et al., 2013). Furthermore, it can be 
added to the arsenal of tools utilized by the FDA as it endeavors to carry its 
mission, that is, to inform the public about harmful costs due to false -
positives and false-negatives as well as due to treatments based on refuted 
concepts and inaccurate or untrustworthy tests and products.  
     Concluding, we would like to remark on the gene-editing revolution that 
our society currently experiences. Clustered Regularly Interspaced Short 
Palindromic Repeat (CRISPR), as stressed by The Scientist (Custom publish- 
ing, October 2016), “is becoming the main procedure to knock-in or knock-
out genes or alter genetic sequences. Due to its simplicity, multiplexing 
capability and reagent availability, researchers are exploring the limits of its 
capabilities in model systems and for clinical applications. Efficient screen- 
ing and detection of gene editing events is critical to successfully generating 
edited cell lines or organisms.”   
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     The potential applications for genetic testing are enormous, given that 
almost every known disease having some aspect that is influenced by, if not 
directly caused by, metamorphoses in the genome of the organism. Genome 
tinkering with demonstrated potential to edit DNA in cell lines and embryos 
is a revolution to reckon with especially because it triggers debates that  
relate to, as stressed by Niemiec et al. (2016), ethical, legal and social issues.  
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     1. As reported by UK’s organization Health Knowledge (2016), “diagnostic tests 
are different than screening tests. The primary purpose of screening tests is to detect 
early disease or risk factors for disease in large numbers of apparently healthy 
individuals. The purpose of a diagnostic test is to establish the presence (or absence) 
of disease as a basis for treatment decisions in symptomatic or screen positive  
individuals (confirmatory test).” Key differences are reported in the following table: 
 
 Screening tests Diagnostic tests 
Purpose To detect potential disease indicators 




Large numbers of asymptomatic, but 
potentially at risk individuals 
Symptomatic individuals to 
establish diagnosis, or 
asymptomatic individuals with a 
positive screening test 
Test method Simple, acceptable to patients and staff 
Maybe invasive, expensive but 





Generally chosen towards high 
sensitivity not to miss potential disease 
Chosen towards high specificity 
(true negatives). More weight given 




Essentially indicates suspicion of 
disease (often used in combination 
with other risk factors) that 
warrants confirmation 
Result provides a definite diagnosis 
Cost 
Cheap, benefits should justify the costs 
since large numbers of people will 
need to be screened to identify a small 
number of potential cases 
Higher costs associated with 
diagnostic test maybe justified to 
establish diagnosis. 
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     2. According to Copi et al. (2007), “Inductive reasoning (as opposed to deductive 
reasoning or abductive reasoning) is reasoning in which the premises are viewed as 
supplying strong evidence for the truth of the conclusion. While the conclusion of a 
deductive argument is certain, the truth of the conclusion of an inductive argument is 
probable, based upon the evidence given.” Conventionally, induction is reasoning 
from specific to general and deduction is reasoning from general to specific. 
     3. See Appendix 1 for more details on the Bayesian Theorem. 
     4. The ROC determines optimal sensitivity and specificity which establishes the 
highest possible degree of a test’s accuracy; and to the extent that diagnostic tests 
generate different ROCs, the ROC closest to the top left enables us to select the most 
useful test, the one with even higher “Sensitivity” and lower “1-Specificity.” 
     5. A theoretical depiction of Graph 2, with continuous data and a certain 
prevalence (e.g., 80%), would look as follows (where TN = Test Negative, TP = 
Test Positive, FN = False-Negative, FP = False-Positive): 
 
As the graph clearly shows, when the cutoff point moves to the right false-negatives 
rise and false-positives fall (vice versa when it moves to the left). Thus, balancing 
this tradeoff between false-negatives and false-positives should be an important goal 
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Appendix 1 Bayesian Theorem, Proof, and Examples 
Simply, if H and E are two disjoint and exhaustive events with probabilities P(H) 
and P(E) greater than zero in a sample space, the conditional probabilities of H given 
E, P(H | E), and E given H, P(E | H), may be stated as follows:  
P(H | E) = P(H and E) | P(E) and P(E | H) = P(E and H) | P(H) or, 
P(H | E)P(E) = P(H and E) and P(H | E)P(H) = P(E and H).                                (1)  
Since the right sides of the equations in (1) are equal, the left sides may be set equal; 
hence, P(H | E)P(E) = P(E | H)P(H).  
Therefore, P(H | E) = P(E | H)P(H) | P(E)                                   (2) 
and P(E | H) = P(H | E)P(E) | P(H)                                          (3) 
Results (2) and (3) are Bayesian probabilities. 
     Generally, the Bayes’ Theorem and its proof may be stated as follows: Consider 
the following figure showing intersections in space W of E with events H1, …, H4.  
 
As per graph above, let the events H1, …, Hk form a partition of the space W such 
that P(Hj) > 0 for j = 1, …, k, and let E be any event such that P(E) > 0. Then for i = 
1, …, k,  
                                                      




Proof: by the definition of conditional probability, P(H i | E) = P(HiE) | P(E).  
The numerator on the right side of (4) is equal to P(H iE) and the denominator is 
equal to P(E). 
     To attempt an explanation about the practical usefulness of Bayesian analysis we 
proceed, without loss of generality, by assuming that theories may be stated, and  
experiments contacted, in terms of two variables summarized in two-variable con- 
tingency tables. Figure A1 portrays a state of nature variable vs. a hypothesis variable. 
 
Figure A1 State of Nature vs. Hypothesis 
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Clinical Illustration: Blood Sugar vs. Physical exercise 
Let variable one be blood sugar level and variable two physical exercise. A doctor 
tests 100 patients for blood sugar levels; 53 of them were diagnosed as high (H)  
blood sugar patients and 47 as low (L) blood sugar patients. Based on this initial 
information, the doctor estimates that the probabilities of high and low are,  
respectively, P(H) = 0.53 and P(L) = 0.47. These probabilities are called the prior 
probabilities.  
     The doctor, in turn, hypothesizes that frequent exercise contributes to low blood 
sugar levels; subject to consent and properly designed incentives (e.g., financial or 
other rewards), she convinces each one of the100 patients to participate in a year-
long clinical experiment designed to reveal whether they exercise frequently (Fr) or 
infrequently (In) subject to a reasonable and objectively chosen cutoff point. The 
cutoff point may consist of hours of exercise per day / week, or other, above (below) 
which exercise is classified as frequent (infrequent). At the end of the year-long 
period, out of the 53 diagnosed as high, 37 exercised infrequently and 16 frequently. 
Out of the 47 diagnosed as low, 19 exercised infrequently and 28 frequently. The 
probabilities that emerge from the doctor’s experiment are called the posterior 
probabilities. Prior and posterior data as well as statistical tests are summarized in 
Figure A2. The results indicate that blood sugar levels and exercise are not  
independent. 
     The posterior probabilities are reported in Figure A2; they are all Bayesian,  
computed similarly to P(T+) and P(T-) as shown below:  
     P(T+) = P(H | In) = [ P(In | H)P(H) | P(In) ] = [ (37 | 53)(53 | 100) | 56 | 100 ] = 
37 | 56 = 0.6607  
     P(T-) = P(L | Fr) = [ P(Fr | L)P(L) | P(Fr) ] = [ (28 | 47)(47 | 100) | 44 | 100 ] = 28 
























































1 0 2  41 3 2  81 13 1 
2 0 2  42 3 2  82 13 2 
3 0 2  43 3 2  83 14 1 
4 0 2  44 3 2  84 14 2 
5 0 2  45 3 2  85 14 1 
6 0 2  46 3 2  86 14 1 
7 0 2  47 4 1  87 14 1 
8 0 2  48 4 2  88 14 2 
9 0 2  49 4 2  89 15 1 
10 1 2  50 4 1  90 15 1 
11 1 2  51 4 2  91 15 1 
12 1 2  52 4 2  92 15 1 
13 1 2  53 5 1  93 16 1 
14 1 2  54 5 2  94 16 1 
15 1 2  55 5 2  95 17 1 
16 1 2  56 5 2  96 17 1 
17 1 2  57 6 1  97 18 1 
18 2 2  58 6 2  98 18 1 
19 2 2  59 6 1  99 19 1 
20 2 2  60 6 2  100 20 1 
21 2 2  61 6 2     
22 2 2  62 6 2     
23 2 2  63 7 2     
24 2 2  64 8 1     
25 2 2  65 8 1     
26 2 2  66 9 1     
27 2 2  67 10 2     
28 2 2  68 10 1     
29 2 2  69 11 1     
30 2 2  70 11 1     
31 2 2  71 12 2     
32 2 2  72 12 2     
33 2 2  73 12 1     
34 2 2  74 12 1     
35 2 2  75 13 2     
36 2 2  76 13 1     
37 2 2  77 13 1     
38 2 2  78 13 2     
39 3 2  79 13 1     
40 3 2  80 13 1     
 
 
